Heart failure
Nov 04, 2016
Neprilysin Inhibitor for Cardiovascular Diseases
According to National Society of Health, approximately 26 million patients are suffering from heart failure worldwide, with the increased economic burden of USD 30.7 billion each year. The advent of a novel class of drugs, i.e., the angiotensin receptor-neprilysin inhibitor, gives hope to the patients. Neprilysin is...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
